Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Philadelphia's Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships


PHILADELPHIA, Oct. 18, 2019 /PRNewswire/ -- Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an upsurge in MPS Antibody Discovery partnerships and the progression of its internal therapeutic antibody pipeline. The new state-of-the-art laboratory space houses specialized equipment including high-throughput robotics and microfluidic biosensors to support the isolation of therapeutic antibodies.

Philadelphia Mayor Jim Kenney was present yesterday at the opening of Integral Molecular's new facility to represent the city's commitment to biotechnology and innovation. "We are thrilled to see Integral Molecular's expansion and continued success in Philadelphia," said Mayor Kenney. "Integral Molecular's growth represents the extraordinary innovation, job creation, and retention of talent in the vibrant and flourishing University City biotechnology hub."

Integral Molecular's second research facility more than doubles its footprint in Philadelphia's uCity Square. University City Science Center Senior Vice President Curt Hess calls Integral Molecular "A poster-child success story of the Science Center." He continues, "We are proud to have supported Integral Molecular from its inception as a two-person company in our incubator through major milestones like its recent expansion. It is interesting to note that Integral Molecular now occupies the laboratory space where Centocor (now part of Janssen Biotech) originated and will carry on the legacy of the successes built in our community."

Integral Molecular's success is based on its innovative approaches in the field of antibody discovery against membrane protein targets. "Our technologies have been recognized as providing an unprecedented success rate of over 95%, generating antibodies against the most difficult targets," said Benjamin Doranz, President of Integral Molecular. In the past year, Integral Molecular has entered research partnerships with numerous companies, including Merus N.V., Ono Pharmaceutical, and Daiichi Sankyo, who are leveraging the MPS Antibody Discovery Platform to obtain antibodies against hard to treat diseases.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in membrane protein solutions, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company's extensive experience optimizing membrane proteins, Integral Molecular's technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Contact:
Integral Molecular, Inc.
Soma Banik, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

SOURCE Integral Molecular


These press releases may also interest you

at 08:15
Vizsla Resources Corp. ("Vizsla Resources" or the "Company") is pleased to announce that it has entered into an agreement with a syndicate of agents led by PI Financial Corp. (collectively, the "Agents") for  a marketed private placement of up to...

at 08:14
Regional Aircraft Leasing segment grows 76% representing 22% of overall adjusted EBT Q3 2019 Financial Highlights and Recent Accomplishments Net income of $24.2 million, or $0.15 per basic Share, a period-over-period decrease of $0.6 million...

at 08:11
Interest from overseas buyers for property in London is increasing and is driven by the weakness in Sterling outweighing the impact of Brexit uncertainty. Research has revealed that the proportion of domestic properties in central London bought by...

at 08:10
The Peck Company , a leading commercial solar engineering, procurement and construction (EPC) company, held a conference call on November 12, 2019 to discuss the Company's third quarter results and its strategic plan. To listen to a telephonic...

at 08:10
China Rapid Finance Limited (the "Company") today announced two developments that mark significant progress in regaining compliance with the New York Stock Exchange's Continued Listing requirements. The Company completed its 2018 financial statement...

at 08:08
The following issues have been halted by IIROC: Company: Canada House Wellness Group Inc. CSE Symbol: CHV (all issues) Reason: At the request of the Company Pending News Halt Time (ET): 8:00 AM IIROC can make a decision to impose a temporary...



News published on 18 october 2019 at 08:00 and distributed by: